speedel.com
Thanks, pgs, for mention of Speedel. I haven't read all their website yet, put the pdf file above provides an overview in bullet points.
SPPN.SW started trading on 9/8/05. At today's quote and currency rates (1 Swiss Franc = $.7745 USD), shares are going for $104, or $718mm market cap. They estimate burn at $47mm (USD) and have $89mm liquid (Sept 05). Only 8,500 shares per day are traded, so this may be hard to buy in the real world.
SPP 301 is in Phase III; an Endothelin A receptor antagonist, partnered with Roche, and being tested in diabetic nephropathy.
There were two renin inhibitor programs listed. SPP 100 is the one with Novartis in hypertension. Some Phase III data must have been released because the company commented that efficacy was good and there was "placebo-like safety". They intend to file NDA next quarter. SPP 635 is an un-partnered renin inhib in Ph I.
There's also a phase II program with Abbott -- SPP 200, a direct thrombin inhibitor. They also mentioned an SPP 600 series, which is unpartnered (but also undescribed).
I need to look a lot further, but particularly want to know terms of the partnerships. Without significant milestones, they'll have to raise new funds in 18 months.
Thanks again for the idea. |
